Brain Protein Blocks Both Key Drivers of Alzheimer's

A protein already known to fight one half of Alzheimer's disease turns out to defend against the other half too, according to groundbreaking research from California scientists.

SORLA, a naturally occurring brain protein, protects against both the amyloid plaques and tau tangles that characterize Alzheimer's disease. Researchers at Sanford Burnham Prebys in La Jolla published their findings July 17, 2026, in Science Advances.

For decades, scientists focused on amyloid plaques, the protein clumps that build up outside brain cells. That research led to FDA-approved drugs like Leqembi and Kisunla. But tau tangles, which form inside neurons, may cause more direct damage to memory and thinking.

Lead researcher Dr. Timothy Huang and his team already knew SORLA could suppress amyloid plaques. The mystery was whether it affected tau tangles too.

To find out, the team created a new mouse model by breeding mice with extra SORLA protein with mice that develop tau tangles and cognitive problems. The results surprised even the scientists.

Mice with elevated SORLA showed dramatically less tau buildup, healthier brain connections, and less brain shrinkage. The protein blocked multiple steps in the tangling process, including stopping toxic tau from recruiting healthy tau proteins into damaging clumps.

"When you upregulate SORLA, you can suppress the negative effects found in tauopathies," said first author Dr. Huijie Huang. "We found there was less brain atrophy and less tau accumulation, which was very exciting to see."

The mice also retained stronger synapses, the critical communication points between brain cells. Their brains showed better plasticity, the ability to form and strengthen connections that underlies learning and memory.

The Bright Side

Finding a protein that tackles both major Alzheimer's pathways is rare in brain research. Most experimental drugs target only one problem, leaving the other unchecked.

This discovery opens a new therapeutic path. Instead of treating plaques and tangles separately, future medicines might boost SORLA levels to address both simultaneously.

The research team plans to study how different brain cell types respond to SORLA changes. They'll also test human neurons and support cells in mouse brains to better understand how the findings might translate to people.

The journey from mouse studies to human treatments typically takes 10 to 15 years. Scientists still need to determine the safest way to increase SORLA in human brains and whether the biological improvements lead to better memory and thinking in the long term.

But for the millions of families touched by Alzheimer's and related dementias, this research represents genuine progress toward therapies that could one day protect the brain from multiple angles at once.

The study received funding from the National Institutes of Health with no competing interests declared.